How were Hemispherx BioPharma's earnings last quarter?

Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) issued its quarterly earnings data on Thursday, August, 15th. The specialty pharmaceutical company reported ($1.07) earnings per share for the quarter, topping the consensus estimate of ($1.70) by $0.63. The specialty pharmaceutical company earned $0.03 million during the quarter.

When did Hemispherx BioPharma's stock split?

Shares of Hemispherx BioPharma reverse split on Tuesday, June 11th 2019. The 1-44 reverse split was announced on Friday, May 31st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 10th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of Hemispherx BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hemispherx BioPharma investors own include NewLink Genetics (NLNK) , Biocept (BIOC) , Goodrich Petroleum (GDPMQ) , Inovio Pharmaceuticals (INO) , Palatin Technologies (PTN) , Biopharmx (BPMX) , CTI BioPharma (CTIC) , Ayala Pharmaceuticals (ADXS) , Cytori Therapeutics (CYTX) and Frontier Communications (FTR) .

How do I buy shares of Hemispherx BioPharma?

Shares of HEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSEAMERICAN:HEB

Hemispherx BioPharma (HEB) Stock Price, News & Analysis

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)

Free HEB Stock Alerts

$0.48

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.45
▼
$0.50
50-Day Range: N/A
52-Week Range: $1.69
▼
$14.81

Volume: 176,741 shs
Average Volume: 102,599 shs
Market Capitalization: $1.16 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Financials SEC Filings

Get Hemispherx BioPharma alerts:

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

About Hemispherx BioPharma Stock (NYSEAMERICAN:HEB)

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.

HEB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HEB Stock News Headlines

April 17, 2024 | americanbankingnews.com

Hemispherx BioPharma (NYSEAMERICAN:HEB) Shares Cross Above 200 Day Moving Average of $0.00

January 7, 2024 | cbsnews.com

H-E-B hosting hiring fairs

April 19, 2024 | TradeSmith (Ad)

The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

October 3, 2023 | chron.com

H-E-B bets on loyal customers as it expands affordable Joe V’s stores

August 28, 2023 | chron.com

H-E-B enters the film world with a five-part docuseries covering Texas parks and wildlife

July 1, 2023 | bizjournals.com

H-E-B opens doors to new Georgetown grocery store

June 27, 2023 | thestreet.com

Hemispherx's Ampligen Dealt FDA Blow

March 29, 2023 | marketwatch.com

YS Biopharma Down 38%; Reports Favorable Covid-19 Vaccine Results

April 19, 2024 | TradeSmith (Ad)

The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

March 11, 2023 | marketwatch.com

First Wave BioPharma Shares Rise 9% After Dosing First Patient With Adrulipase

February 26, 2023 | dallasnews.com

H-E-B plans to hire 700 for its McKinney store

January 26, 2023 | dallasnews.com

H-E-B worker starts petition over grocer’s sick policy after testing positive for COVID

January 12, 2023 | dallasnews.com

H-E-B starts its plans for a second Frisco store near Little Elm

January 12, 2023 | bizjournals.com

H-E-B working on plans for a second Frisco store — this time near Little Elm

October 29, 2022 | bizjournals.com

Are you ready for another H-E-B? Fort Worth location will break ground soon

September 23, 2022 | bizjournals.com

Here's everything you need to know about H-E-B Frisco, which opens today

September 17, 2022 | thestreet.com

Ebola Outbreak Puts the Spotlight on 10 Biotech Companies

August 24, 2022 | thestreet.com

Hemispherx CEO Spills Ampligen Beans to Stock Cheerleader: BioBuzz

May 31, 2022 | news.yahoo.com

Organic Strawberries Tied to a Hepatitis A Outbreak Are Being Recalled Across North America

See More Headlines

Receive HEB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hemispherx BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/15/2019
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NYSEAMERICAN:HEB
Previous Symbol: NYSE:HEB
CUSIP: N/A
CIK: 946644
Web: www.hemispherx.net
Phone: +1-407-2718516
Fax: N/A
Employees: 31
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 2,442,000
Free Float: N/A
Market Cap: $1.16 million
Optionable: Not Optionable
Beta: N/A

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Mr. Thomas K. Equels (Age 66)
Exec. Vice Chairman, CEO & Pres
Mr. Adam Pascale (Age 71)
Chief Financial Officer
Mr. Peter W. Rodino III (Age 68)
J.D., Exec. Director of Gov.al Relations, Gen. Counsel & Sec.
Mr. Wayne S. Springate (Age 48)
Sr. VP of Operations
Ms. Ellen Lintal
Chief Accounting Officer

Key Competitors

View All Competitors

HEB Stock Analysis - Frequently Asked Questions

How were Hemispherx BioPharma's earnings last quarter?: Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) issued its quarterly earnings data on Thursday, August, 15th. The specialty pharmaceutical company reported ($1.07) earnings per share for the quarter, topping the consensus estimate of ($1.70) by $0.63. The specialty pharmaceutical company earned $0.03 million during the quarter.
When did Hemispherx BioPharma's stock split?: Shares of Hemispherx BioPharma reverse split on Tuesday, June 11th 2019. The 1-44 reverse split was announced on Friday, May 31st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 10th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.
What other stocks do shareholders of Hemispherx BioPharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Hemispherx BioPharma investors own include NewLink Genetics (NLNK), Biocept (BIOC), Goodrich Petroleum (GDPMQ), Inovio Pharmaceuticals (INO), Palatin Technologies (PTN), Biopharmx (BPMX), CTI BioPharma (CTIC), Ayala Pharmaceuticals (ADXS), Cytori Therapeutics (CYTX) and Frontier Communications (FTR).
How do I buy shares of Hemispherx BioPharma?: Shares of HEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:HEB) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial